Vertex Pharmaceuticals: Solid Q2 Beat and Raised 2026 Guidance, But Early-Stage Diversification and CRNX Integration Keep Rating at Hold

TIPRANKS08-04

Needham analyst Joseph Stringer has maintained their neutral stance on VRTX stock, giving a Hold rating today. Joseph Stringer has given his Hold r...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2656551739?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-04 21:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2656551739","market":"fut","top_or_hot":-1,"title":"Vertex Pharmaceuticals: Solid Q2 Beat and Raised 2026 Guidance, But Early-Stage Diversification and CRNX Integration Keep Rating at Hold","media":"TIPRANKS","content":"<div>\n<p>Needham analyst Joseph Stringer has maintained their neutral stance on VRTX stock, giving a Hold rating today. Joseph Stringer has given his Hold r...</p>\n\n<a href=\"https://www.tipranks.com/news/ratings/vertex-pharmaceuticals-solid-q2-beat-and-raised-2026-guidance-but-early-stage-diversification-and-crnx-integration-keep-rating-at-hold-ratings-news?utm_source=itigerup.com&utm_medium=referral\">Source Link</a>\n\n</div>\n","source":"tipranks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vertex Pharmaceuticals: Solid Q2 Beat and Raised 2026 Guidance, But Early-Stage Diversification and CRNX Integration Keep Rating at Hold</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVertex Pharmaceuticals: Solid Q2 Beat and Raised 2026 Guidance, But Early-Stage Diversification and CRNX Integration Keep Rating at Hold\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-04 21:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.tipranks.com/news/ratings/vertex-pharmaceuticals-solid-q2-beat-and-raised-2026-guidance-but-early-stage-diversification-and-crnx-integration-keep-rating-at-hold-ratings-news?utm_source=itigerup.com&utm_medium=referral><strong>TIPRANKS</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Needham analyst Joseph Stringer has maintained their neutral stance on VRTX stock, giving a Hold rating today. Joseph Stringer has given his Hold r...</p>\n\n<a href=\"https://www.tipranks.com/news/ratings/vertex-pharmaceuticals-solid-q2-beat-and-raised-2026-guidance-but-early-stage-diversification-and-crnx-integration-keep-rating-at-hold-ratings-news?utm_source=itigerup.com&utm_medium=referral\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VERX","symbol_name":"Vertex, Inc.","start_time":0,"source_url":"https://www.tipranks.com/news/ratings/vertex-pharmaceuticals-solid-q2-beat-and-raised-2026-guidance-but-early-stage-diversification-and-crnx-integration-keep-rating-at-hold-ratings-news?utm_source=itigerup.com&utm_medium=referral","article_id":"2656551739","we_media_id":null,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/vertex-pharmaceuticals-solid-q2-beat-and-raised-2026-guidance-but-early-stage-diversification-and-crnx-integration-keep-rating-at-hold-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2656551739","pubTimestamp":1785850911,"columns":[],"sourceInfo":{"source_id":"tipranks_highlight","name":"Tipranks"},"weMediaInfo":null,"summary":"Needham analyst Joseph Stringer has maintained their neutral stance on VRTX stock, giving a Hold rating today. Joseph Stringer has given his Hold r...","collect":0,"end_time":0,"defaultTopTitle":"tipranks.com","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"VERX":"Vertex, Inc.","CRNX":"Crinetics Pharmaceuticals Inc.","VRTX":"福泰制药"},"translate_title":"Vertex Pharmaceuticals：第二季度表现强劲并上调了 2026 年指引，但早期多元化和 CRNX 整合维持评级不变","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VERX":1.5,"VRTX":1.5,"CRNX":1.5},"content_text":"Needham analyst Joseph Stringer has maintained their neutral stance on VRTX stock, giving a Hold rating today. Joseph Stringer has given his Hold r...","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2656551739","isCrawlerRequest":true}